Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis
Crossref DOI link: https://doi.org/10.1007/s00432-015-1910-9
Published Online: 2015-01-11
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ying, Min
Zhu, Xiaoxia
Chen, Kexu
Sha, Zhou
Chen, Longhua
Text and Data Mining valid from 2015-01-11